By Kosaku Narioka
Takeda Pharmaceutical is scheduled to report its fourth-quarter results on Thursday. Here's what you need to know:
NET LOSS FORECAST: Takeda is expected to post a net loss of 81.7 billion yen, equivalent to $573.7 million, for the three months ended March, according to a Visible Alpha poll of analysts. That compares with a net loss of Y3.0 billion in the year-earlier period.
REVENUE FORECAST: Fourth-quarter revenue is estimated to have risen 2.3% on year to Y1.076 trillion, the poll shows.
Shares have gained 3.2% so far this year after rising a 3.1% in 2024.
WHAT TO WATCH:
--Takeda is expected to provide fiscal-year guidance, with investors eyeing sales and profit forecasts as well as any comments on potential U.S. tariffs.
--Investors will monitor sales momentum of key drugs. Third-quarter sales of ulcerative colitis drug Entyvio fell 0.8% to Y225.8 billion, while plasma-derived products rose 1.7% to Y248.5 billion.
--Margin trends will also be in focus after operating profit margin declined to 5.9% in the third quarter from 9.4% a year earlier amid global inflation pressures.
Write to Kosaku Narioka at kosaku.narioka@wsj.com
(END) Dow Jones Newswires
May 07, 2025 07:11 ET (11:11 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。